Abstract: Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients- P. Cacoub, et. al.
Source: AHJ April 2018; Volume 198, Pages 4–17 https://doi.org/10.1016/j.ahj.2017.10.024
Study Aims and Results: The objective was to examine the impact of HCV cure on major adverse cardiovascular (heart disease) events (MACEs) in patients with compensated hepatitis C (HCV) cirrhosis. MACEs included stroke, myocardial infarction, ischemic heart disease, heart failure, peripheral arterial disease, cardiac arrest, and cardiovascular death. There were 878 patients followed for a median of 58 months for the period ending December 2015.
Sixty-two of 878 (7%) patients had a total of 79 MACE events. The main predictive values of MACE included Asian origin, history of MACEs, arterial hypertension (high blood pressure), type 2 diabetes, current smoking, low serum albumin level, high bilirubin level, and low platelet count.
Curing HCV was associated with a decreased risk of MACE events, but Asian origin, arterial hypertension, smoking, and low serum albumin level remained predictive of MACE occurrences. In those who had MACE before being cured, the 5-year survival rate was 60% compared to the survival rate of 88% in the people who did not have MACEs.
Conclusions: Curing HCV decreases the rate of heart disease whereas in patients with HCV-related compensated cirrhosis, Asian ethnic origin, arterial hypertension, smoking, and low serum albumin are independent predictive factors of heart disease.
Curing people of HCV increases the survival rate from MACEs but having MACEs before treatment reduces overall survival from MACE events even after being cured of HCV.
Editorial Comments: This is another reason why we should be treating HCV early before disease progression occurs and treating MACE and other health issues that may or may not be caused by HCV.
Share This Page